Oxalo Therapeutics

Chicago, IL

UEI
JD11RKB2KWJ3
CAGE
81RX8
Primary NAICS
Not on record
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Minority Owned Business
  • For Profit Organization
  • Black American Owned
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
1452 E 53rd St 2nd floor, Chicago, IL 60615, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Sttr phase II: developing a novel drug delivery system to enable an oral peptide-based drug for kidney stones 2200058 National Science Foundation $999,999
Sttr phase i: developing a novel drug delivery system to enable an oral peptide based drug for kidney stones 1914232 Division of Industrial Innovation $224,995
Developing a peptide-based oral drug to prevent kidney stones R42DK120261 National Institute of Diabetes and Digestive and Kidney Diseases (NIH) $2,299,991

Quick answers

Is Oxalo Therapeutics registered in SAM.gov?

Yes. Oxalo Therapeutics's SAM.gov registration is active through April 24, 2027.

What is Oxalo Therapeutics's most recent federal award?

Oxalo Therapeutics's most recent federal grant award is Sttr phase II: developing a novel drug delivery system to enable an oral peptide-based drug for kidney stones (2200058), from National Science Foundation, on April 15, 2022.

On GovTribe

See Oxalo Therapeutics's full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login